🔬 PubMed Lab Free · No signup
Search PubMed with a plain-English research question, then chat with an AI about any paper. Powered by Claude (Anthropic) + NIH PubMed E-utilities.
-
GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetit…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.
Glucagon-like peptide-1 (GLP-1) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. GLP-1 receptor agonists are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential target for addi…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
GLP-1a: Going beyond Traditional Use.
Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating d…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
The emerging role of glucagon-like peptide 1 in binge eating.
Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycem…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
Satiety: a gut-brain-relationship.
Many hormones act on the hypothalamus to control hunger and satiety through various pathways closely associated with several factors. When food is present in the gastro intestinal (GI) tract, enteroendocrine cells (EECs) emit satiety signals such as cholecystokinin (CCK), glucagon like peptide-1 (GLP-1) and peptide YY (PYY), which can then communicate with the vagus nerve to control food intake. M…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.
BackgroundAlcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts for 5% of deaths annually, and there is an urgent need to develop new targets for therapeutic intervention. The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide reduces alcohol consumption in rodents and nonhuman primates, but its efficacy in patients with AUD is unknown.MethodsIn a randomized, doub…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.
Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, have recently gained attention for their potential effects on addictive behaviors. Preclinical and early clinical studies suggest that GLP-1RAs modulat…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review.
The roles of metabolic signals, including Glucagon-like peptide 1 (GLP-1), have been implicated in multiple domains outside metabolic regulation. There is a growing interest in repurposing Glucagon-like peptide 1 receptor agonists (GLP-1RAs) as therapeutics for motivation and reward-related behavioural disturbances. Herein, we aim to systematically review the extant evidence on the potential effec…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.
Binge eating disorder (BED) is a prevalent eating disorder lacking adequate pharmacological interventions. This review examines the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), medications approved for type 2 diabetes and obesity now being investigated for eating disorders through their modulation of metabolic and reward pathways. A narrative review was conducted …
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
-
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.
Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD). However, the probability of low semaglutide doses, an agonist with higher potency and affinity for GLP-1R, to attenuate alcohol-related responses in rodents and the underlying neuronal mechanisms is unknown. In the intermittent access mode…
💬 Chat with AI about this paper (β) Remaining 3 / 3 todayAnswers use only the paper's abstract. Not medical advice. Missing info returns "not stated in abstract."Question examples: "Summarize the 3 key findings" · "Limitations?" · "N and statistical method?" · "Possible counter-argument?"
❓ How it works
What does this do?
You type a research question in English. We query the NIH PubMed database and show the top 10 most relevant. Click "💬 Chat with AI" below any paper to ask questions about its methods, findings, and limitations — inline, right below the paper.
Is this free?
Yes, and no signup is required. Funded by affiliate links + ads elsewhere on the site.
Any usage limit?
3 chat messages per browser per day (cost control). Search itself is unlimited.
Do you store my queries?
Queries appear in server logs (retained ~14 days for abuse prevention) and are sent to Anthropic's Claude API for chat (Anthropic's terms apply). Not sold to third parties.
Medical disclaimer?
The AI answers are general education, not medical advice. Consult a qualified professional for any health decision. See our editorial policy.